Department of Nuclear Medicine, Spedali Civili Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy.
Department of Nuclear Medicine, University of Brescia, Brescia, Italy.
Abdom Radiol (NY). 2016 Oct;41(10):1956-9. doi: 10.1007/s00261-016-0800-1.
Primary hepatic mucosa-associated lymphoid tissue (MALT) lymphoma is an extremely rare disease and its glucidic metabolic behavior is not clear. We retrospectively analyzed five patients with histological diagnosis of primary hepatic MALT lymphoma who underwent twelve 18F-FDG PET/CT. All staging 18F-FDG PET/CT were positive showing 18F-FDG uptake (average SUVmax was 5.62 ± 1.6) at the corresponding liver lesion. 18F-FDG PET/CT also was useful in evaluating the complete metabolic response after chemotherapy in three patients and radiotherapy in two. Besides, in one patient 18F-FDG PET/CT detected disease relapse during follow-up. Despite the low number of patients, our case series shows the 18F-FDG avidity of hepatic MALT and the possible role of 18F-FDG PET/CT in the management of these patients, both for staging, treatment response evaluation and restaging. Further studies are needed to confirm our results.
原发性肝脏黏膜相关淋巴组织(MALT)淋巴瘤是一种极其罕见的疾病,其糖代谢行为尚不清楚。我们回顾性分析了 5 例经组织学诊断为原发性肝脏 MALT 淋巴瘤并接受 12 次 18F-FDG PET/CT 检查的患者。所有分期 18F-FDG PET/CT 均为阳性,在相应的肝脏病变处显示 18F-FDG 摄取(平均 SUVmax 为 5.62±1.6)。18F-FDG PET/CT 还可用于评估 3 例患者化疗和 2 例患者放疗后的完全代谢反应。此外,在 1 例患者的随访中,18F-FDG PET/CT 检测到疾病复发。尽管患者数量较少,但我们的病例系列表明肝脏 MALT 的 18F-FDG 摄取,以及 18F-FDG PET/CT 在这些患者的管理中的可能作用,包括分期、治疗反应评估和重新分期。需要进一步的研究来证实我们的结果。